Three months ago, health insurer stocks cratered when the Trump administration floated a Medicare Advantage rate increase of just 0.09% for 2027. Practically nothing. Barely a rounding error. The market read it as an implicit attack on an industry that had already been struggling with rising medical costs, and shares of UnitedHealth Group, Humana, and CVS Health got crushed.
On Monday, Washington reversed course — and then some.
The Centers for Medicare & Medicaid Services finalized a 2.48% average payment increase for Medicare Advantage plans in 2027, translating to more than $13 billion flowing into the industry. The reaction was immediate and violent: UnitedHealth and CVS Health each jumped more than 9% in after-hours trading. Humana, which had more to gain given its heavier MA exposure, surged around 12%.
That’s not a small move for companies of this size. Humana alone has a market cap north of $25 billion. A 12% single-session pop represents roughly $3 billion in market value conjured out of one government press release.
Why This Number Matters So Much
Medicare Advantage is the engine of the modern health insurance industry. More than half of all Medicare beneficiaries — over 33 million Americans — are now enrolled in these privately-run plans, attracted by lower premiums and extra benefits traditional Medicare doesn’t offer. For insurers, it’s a massive, captive pool of customers backstopped by federal payments.
Here’s the thing: the math is tight. Insurers price their plans based on what they expect to receive from the government offset against what they expect to pay out in medical claims. When that spread narrows — as it did through much of 2024 and 2025, when medical costs ran hotter than expected — profits evaporate. Humana spent much of last year warning investors that its MA business was essentially losing money on a per-member basis.
A 0.09% rate hike in that environment isn’t a gift. It’s a slow squeeze. The January proposal spooked the market precisely because it suggested the administration either didn’t understand the industry’s cost pressures, or didn’t care about them.
Monday’s finalized rate suggests a different read.
The Oz Factor
CMS Administrator Dr. Mehmet Oz — yes, that Dr. Oz — put his name on the announcement. “Medicare Advantage and Part D should work for the people who rely on them,” he said in the release. “These updates keep coverage affordable and ensure patients get real value from their plans.”
Read between the lines: the administration was hearing from seniors, insurers, and their congressional allies that a flat rate was untenable. MA enrollment has exploded over the past decade, and those 33 million-plus beneficiaries vote. Pummeling the plans they rely on is bad politics in an election year, regardless of what party you belong to.
To be fair, 2.48% isn’t a windfall. Medical inflation is still running hot, and insurers will need to demonstrate they can manage claims costs alongside the payment increase. The rate helps, but it doesn’t solve everything.
What It Means for the Stocks
The after-hours surge reflects relief more than euphoria. These stocks had been dead weight in portfolios all year. UnitedHealth, down nearly 20% from its 2025 highs, needed a catalyst. This is it — but the magnitude of the move also tells you just how bearish sentiment had become.
Humana is the most direct beneficiary. The company has been almost entirely dependent on Medicare Advantage for revenue growth, and management spent most of last year in full damage-control mode after repeatedly missing earnings estimates. A 2.48% rate increase doesn’t erase those structural problems, but it gives management room to breathe and reprice plans for 2027 with actual margin cushion.
CVS Health is a different animal. Its Aetna unit runs a significant MA business, but CVS is also battling headwinds in its pharmacy and retail segments. The rate news helps, but don’t mistake a 9% pop for a total-company turnaround story.
UnitedHealth is the 800-pound gorilla. It operates the country’s largest MA plan through its UnitedHealthcare subsidiary. The rate increase directly improves its 2027 outlook, and the market is pricing that in fast. Wall Street analysts who had been cautious on the stock are likely revisiting their models tonight.
The Broader Backdrop
This announcement lands in a strange market environment. Investors are simultaneously watching Treasury yields hold near 4.3%, waiting for Friday’s CPI print — the first since the Iran war started — and checking their phones every hour for updates on Trump’s Tuesday deadline to reopen the Strait of Hormuz.
In that context, a sector-specific catalyst for health insurers is actually a useful diversifier. Energy, defense, and commodities have dominated the narrative for six weeks. Healthcare had been largely forgotten. Monday’s CMS announcement is a reminder that domestic policy decisions can still move stocks even when geopolitics is eating everyone’s attention.
The question now is whether the move holds when Tuesday morning opens. After-hours pops don’t always survive the light of day. If oil headlines dominate again and risk sentiment sours, some of those gains could fade. But the underlying change is real: the regulatory backdrop for Medicare Advantage just got meaningfully better, and that isn’t reversing overnight.
Sometimes the most important market-moving story of the day has nothing to do with the war everyone’s watching.
Disclosure: This article is for informational purposes only and is not investment advice.